Technical Analysis for C4XD - C4X Discovery Holdings plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 9.43 | 4.72% | 0.43 |
Earnings due: Apr 24
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 4.72% | |
| Wide Bands | Range Expansion | 4.72% | |
| Volume Surge | Other | 15.29% | |
| Doji - Bullish? | Reversal | 15.29% | |
| New 52 Week Low | Weakness | 15.29% |
| Alert | Time |
|---|---|
| Possible NR7 | about 9 hours ago |
| 10 DMA Support | about 11 hours ago |
| Down 1% | about 13 hours ago |
| Fell Below 10 DMA | about 13 hours ago |
| 3x Volume Pace | about 14 hours ago |
Get a Trading Sidekick!
C4X Discovery Holdings plc Description
C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biopharmaceutical Biology Drug Discovery Autoimmune Diseases Diabetes Health Sciences Chronic Obstructive Pulmonary Disease Autoimmune Disease Psoriasis Inflammatory Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.985 |
| 52 Week Low | 7.0 |
| Average Volume | 1,206,497 |
| 200-Day Moving Average | 14.28 |
| 50-Day Moving Average | 11.25 |
| 20-Day Moving Average | 9.29 |
| 10-Day Moving Average | 8.92 |
| Average True Range | 1.49 |
| RSI (14) | 46.52 |
| ADX | 26.93 |
| +DI | 14.17 |
| -DI | 22.68 |
| Chandelier Exit (Long, 3 ATRs) | 10.58 |
| Chandelier Exit (Short, 3 ATRs) | 11.47 |
| Upper Bollinger Bands | 11.53 |
| Lower Bollinger Band | 7.06 |
| Percent B (%b) | 0.53 |
| BandWidth | 48.13 |
| MACD Line | -0.79 |
| MACD Signal Line | -0.85 |
| MACD Histogram | 0.0636 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.60 | ||||
| Resistance 3 (R3) | 10.53 | 10.07 | 10.41 | ||
| Resistance 2 (R2) | 10.07 | 9.77 | 10.11 | 10.34 | |
| Resistance 1 (R1) | 9.75 | 9.59 | 9.91 | 9.82 | 10.28 |
| Pivot Point | 9.29 | 9.29 | 9.37 | 9.32 | 9.29 |
| Support 1 (S1) | 8.97 | 8.99 | 9.13 | 9.03 | 8.57 |
| Support 2 (S2) | 8.51 | 8.80 | 8.54 | 8.51 | |
| Support 3 (S3) | 8.18 | 8.51 | 8.44 | ||
| Support 4 (S4) | 8.25 |
